City Therapeutics Inc CTY

$21.46 -0.94 (-4.20%)

Valuation

Market cap
—
Revenue TTM
$13,562,000
Net income TTM
$-58,505,000
PE ratio
—
Forward PE
—
Profit margin
-431.39%
Debt to equity
—

Trading

Volume
302,300
Avg volume
—
Day's range
$21.03 – $22.00
Shares out
—
Stochastic %K
—
Beta
—
Analysts
Strong Buy
Price target
—

Price

Stocktwits

DomJonno1 Oct 29, 7:42 AM
$CTY plenty in the pipeline, sold financials I’m in
0 replies
openmarketalerts Oct 20, 2:02 PM
Cluster buys filed Mon, Oct 19 $CTY City Therapeutics — 2 insiders bought $6.1M (Oct 19) $FUL Fuller H B Co — 9 insiders bought $1.1M (Sep 28 – Oct 16) $SNES SenesTech — 2 insiders bought $707K (Sep 28 – Oct 19) $APLD Applied Digital — 2 insiders bought $6.7M (Oct 16)
0 replies
IPOtweet Oct 20, 1:21 PM
This week's IPO Winners & Losers podcast featured discussions on Anthropic's looming IPO, the AI selloff, biotech's quick comeback, and more. Watch here 👉 https://www.youtube.com/watch?v=7HZuESQKzHg #IPO #NewStocks #Anthropic $CTY $IAM $IPO
0 replies
openmarketalerts Oct 19, 11:25 PM
$CTY — Director Nelsen Robert bought $3.1M of stock on Oct 19. • 170,000 shares at $18.00. • Stake up 1.3%.
0 replies
topstockalerts Oct 19, 9:14 PM
City Therapeutics, a Cambridge, Massachusetts-based clinical-stage biotech focused on RNA interference (RNAi) therapeutics, completed its IPO, raising approximately $230 million in gross proceeds before underwriting discounts, commissions and other expenses. The company sold 12,777,777 shares of common stock at $18 per share, including 1,666,666 shares issued after underwriters fully exercised their overallotment option. All shares were offered by the company. The stock began trading on the Nasdaq Global Market on October 16, 2026, under its ticker, following the effectiveness of its registration statements on October 15. Goldman Sachs, Jefferies, Stifel and Oppenheimer acted as joint book-running managers. City Therapeutics’ pipeline includes CITY-FXI, targeting thromboembolic diseases; CITY-RBP4, focused on Stargardt disease and other retinal disorders; and CITY-TFR2, aimed at treating anemia associated with chronic diseases. $CTY
1 replies
BiotechSwings Oct 18, 4:26 PM
$CTY debuted Friday and just ignored the whole sector mood. priced $18, opened $23, closed $22.40, up 24 percent day one while $XBI lost 3.65 percent upsized raise, about $200 million in, RNAi for clots, Stargardt and anemia. imo that is not a closed IPO window. that is a selective one
0 replies
Ric_1M Oct 18, 12:46 PM
$PMI $IAM $CTY $POAS $CCEL "The law of attraction states that whatever you focus on, think about, read about, and talk about intensely, you’re going to attract more of into your life." Jack Canfield
1 replies
Georgia80 Oct 17, 3:10 PM
$CTY needing more volume and watchers
0 replies